Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance

doi:10.5498/wjp.v13.i11.937

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 11

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6081)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

174

WORD

HTML

2772

Figures (1-1)

492

Tables (1-7)

488

Sum=3961

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

368

Download

1544

Sum=1912

Nov 19, 2023 (publication date) through Mar 18, 2026

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Psychiatry. Nov 19, 2023; 13(11): 937-948
Published online Nov 19, 2023. doi: 10.5498/wjp.v13.i11.937

Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance

Yu-Mei Wei, Xi-Jin Wang, Xiao-Dong Yang, Chuan-Sheng Wang, Li-Li Wang, Xiao-Ying Xu, Gui-Jun Zhao, Bin Li, Dao-Min Zhu, Qi Wu, Yi-Feng Shen

Yu-Mei Wei, Shanghai Clinical Research Center for Mental Health, School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, China

Xi-Jin Wang, Department of Psychiatry, The First Psychiatric Hospital of Harbin, Harbin 150056, Heilongjiang Province, China

Xiao-Dong Yang, Department of Psychiatry, Shandong Provincial Mental Health Center, Jinan 250014, Shandong Province, China

Chuan-Sheng Wang, Department of Psychiatry, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, Henan Province, China

Li-Li Wang, Department of Psychiatry, Tianjin Mental Health Center, Tianjin Anding Hospital, Tianjin 300222, China

Xiao-Ying Xu, Department of Psychiatry, The Fifth People’s Hospital of Zigong, Zigong 643020, Sichuan Province, China

Gui-Jun Zhao, Department of Psychiatry, Guangyuan Mental Health Center, Guangyuan 628001, Guizhou Province, China

Bin Li, Department of Psychology, Fujian Energy General Hospital, Fuzhou 350001, Fujian Province, China

Dao-Min Zhu, Department of Sleep Disorders, Affiliated Psychological Hospital of Anhui Medical University, Hefei Fourth People’s Hospital, Anhui Mental Health Center, Hefei 230022, Anhui Province, China

Qi Wu, Sumitomo Pharma (China), Co., Ltd., Shanghai 200025, China

Yi-Feng Shen, Shanghai Key Laboratory of Psychotic Disorders, Shanghai Clinical Research Center for Mental Health, Shanghai Jiao Tong University, Shanghai 200030, China

Author contributions: Wang XJ, Yang XD, Wang CS, Wang LL, Xu XY, Zhao GJ, Li B, Zhu DM and Shen YF contributed to data acquisition, data analysis and interpretation; Wei YM and Wu Q contributed to the study concept, design and data analysis; All authors read and approved the final manuscript.

Supported by Collaborative Innovation Center Project of Translational Medicine, Shanghai Jiaotong University School of Medicine, No. TM202116PT (2021-2023); Clinical Research Plan of SHDC, No. SHDC2022CRS032; and the Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.

Institutional review board statement: The study protocol was approved by the ethics committees of Shanghai Mental Health Center (the leading site) and other sites.

Informed consent statement: The patients were required to provide informed consent before participating.

Conflict-of-interest statement: The authors declare no conflicts of interest.

Data sharing statement: No additional data are available.

Corresponding author: Yi-Feng Shen, MD, PhD, Professor, Shanghai Key Laboratory of Psychotic Disorders, Shanghai Clinical Research Center for Mental Health, Shanghai Jiao Tong University, No. 600 Wanping Nan Road, Shanghai 200030, China, Shanghai 200030, China. shenyifeng@sina.com

Received: August 23, 2023
Peer-review started: August 23, 2023
First decision: September 28, 2023
Revised: October 11, 2023
Accepted: October 27, 2023
Article in press: October 27, 2023
Published online: November 19, 2023
Processing time: 86 Days and 2.6 Hours

ARTICLE HIGHLIGHTS

Research background

Schizophrenia is a psychiatric disorder characterized by chronic or recurrent symptoms. Lurasidone was licensed in China in 2019 for the treatment of adult schizophrenia in adults.

Research motivation

To further validate the safety profile and effectiveness of lurasidone.

Research objectives

To evaluate the safety and effectiveness of lurasidone in the Chinese population.

Research methods

We conducted a prospective, multicenter, open-label, 12-wk surveillance in mainland China, and reported the interim analysis based on 965 patients who received the medication between 2019 and 2022.

Research results

Mean changes in total brief psychiatric rating scale scores were -8.9 ± 9.76 (n = 959), -13.5±12.29 (n = 959), and -16.8 ± 13.97 (n = 959) after 2/4, 6/8, and 12 wk, respectively (P < 0.001 for each visit compared with the baseline) using the last-observation-carried-forward method. adverse events and adverse drug reactions were experienced by 101 (11.3%) and 78 patients (8.7%), respectively, which were mostly mild.

Research conclusions

The interim analysis of the post-market surveillance demonstrate the safety and effectiveness of lurasidone in the Chinese population.

Research perspectives

This study contributes additional safety and effectiveness data on lurasidone, surpassing those obtained in pre-marketing trials. It offers essential guidance for clinical decision-making in the treatment of schizophrenia.